/

Empresas

Fr

No verificado

Fresenius Kabi

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaSaludSanidad

35 Comunicados de prensa

Ver todos los comunicados de prensa

20/01/2026

Fresenius Kabi Recognized as a Top Employer in the United States for the Fourth Consecutive Year

Fuente

Editor

1.00

0

14/01/2026

Multimedia

Industria

Higiene alimentaria

Biotecnología

Salud

Farmacéutica

Sanidad

Oncología

Mercado laboral

Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement

Fuente

Editor

1.00

0

06/01/2026

Fresenius Kabi Introduces New Presentation of Otulfi® (ustekinumab-aauz), a Biosimilar to Stelara®

Fuente

Editor

1.00

0

18/12/2025

Fresenius Kabi Introduces First-Ever Rocuronium Bromide Injection Stable at Room Temperature

Fuente

Editor

1.00

0

02/12/2025

Fresenius Kabi Expands Operating Room Portfolio with New Simplist® Prefilled Syringes

Fuente

Editor

1.00

0

24/11/2025

Fresenius Kabi Introduces Dalbavancin for Injection (for single-dose regimen use only)

Fuente

Editor

1.00

0

12/11/2025

Industria

Medicina - Varios

Biotecnología

Biología

Sanidad

Farmacéutica

Salud

Oncología

Fresenius Kabi’s Adaptive Nomogram used on Aurora Xi Plasmapheresis System Now Operating Nationwide at BioLife Plasma Centers

Fuente

Editor

1.00

0

12/11/2025

CORRECTING and REPLACING Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2 mL Fill in a 2 mL Vial Due to Out-of-Specification Endotoxin Results in Certain Reserve Samples

Fuente

Editor

1.00

0

07/11/2025

Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2 mL Fill in a 2 mL Vial Due to Out-of-Specification Endotoxin Results in Certain Reserve Samples

Fuente

Editor

1.00

0

29/10/2025

Industria

Biotecnología

Higiene alimentaria

Salud

Farmacéutica

Oncología

FDA Grants Interchangeable Designation to Fresenius Kabi’s Biosimilars Conexxence® and Bomyntra® (denosumab-bnht)

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0